Community-acquired pneumonia in adults (non Covid-19)

References

Key articles

Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-67.Full text  Abstract

Reference articles

1. Simonetti AF, Viasus D, Garcia-Vidal C, et al. Management of community-acquired pneumonia in older adults. Ther Adv Infect Dis. 2014 Feb;2(1):3-16.Full text  Abstract

2. Masiá M, Gutiérrez F, Padilla S, et al. Clinical characterisation of pneumonia caused by atypical pathogens combining classic and novel predictors. Clin Microbiol Infect. 2007 Feb;13(2):153-61.Full text  Abstract

3. Institute for Health Metrics and Evaluation. Lower respiratory infections — level 3 cause. 2019 [internet publication].Full text

4. GBD 2019 Diseases and Injuries Collaborators. Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. Lancet. 2020 Oct 17:396(10258):1204-22.Full text  Abstract

5. Jain S, Self WH, Wunderink RG, et al. Community-acquired pneumonia requiring hospitalization among US adults. N Engl J Med. 2015 Jul 30;373(5):415-27.Full text  Abstract

6. Kochanek KD, Murphy SL, Xu J, et al. Deaths: final data for 2016. Natl Vital Stat Rep. 2018 Jul;67(5):1-76.Full text  Abstract

7. McLaughlin JM, Khan FL, Thoburn EA, et al. Rates of hospitalization for community-acquired pneumonia among US adults: a systematic review. Vaccine. 2020 Jan 22;38(4):741-51.Full text  Abstract

8. Rice LB. Antimicrobial resistance in gram-positive bacteria. Am J Med. 2006 Jun;119(suppl 1):S11-9. Abstract

9. Cillóniz C, Ewig S, Polverino E, et al. Microbial aetiology of community-acquired pneumonia and its relation to severity. Thorax. 2011 Apr;66(4):340-6.Full text  Abstract

10. Cillóniz C, Ewig S, Polverino E, et al. Community-acquired pneumonia in outpatients: aetiology and outcomes. Eur Respir J. 2012 Oct;40(4):931-8.Full text  Abstract

11. Cilloniz C, Torres A, Polverino E, et al. Community-acquired lung respiratory infections in HIV-infected patients: microbial aetiology and outcome. Eur Respir J. 2014 Jun;43(6):1698-708.Full text  Abstract

12. Almirall J, Boixeda R, Bolíbar I, et al. Differences in the etiology of community-acquired pneumonia according to site of care: a population-based study. Respir Med. 2007 Oct;101(10):2168-75.Full text  Abstract

13. Alimi Y, Lim WS, Lansbury L, et al. Systematic review of respiratory viral pathogens identified in adults with community-acquired pneumonia in Europe. J Clin Virol. 2017 Oct;95:26-35. Abstract

14. Almirall J, Bolíbar I, Vidal J, et al. Epidemiology of community-acquired pneumonia in adults: a population-based study. Eur Respir J. 2000 Apr;15(4):757-63.Full text  Abstract

15. Torres A, Cillóniz C, Blasi F, et al. Burden of pneumococcal community-acquired pneumonia in adults across Europe: a literature review. Respir Med. 2018 Apr;137:6-13. Abstract

16. Marchello C, Dale AP, Thai TN, et al. Prevalence of atypical pathogens in patients with cough and community-acquired pneumonia: a meta-analysis. Ann Fam Med. 2016 Nov;14(6):552-66.Full text  Abstract

17. Arnold FW, Summersgill JT, Ramirez JA. Role of atypical pathogens in the etiology of community-acquired pneumonia. Semin Respir Crit Care Med. 2016 Dec;37(6):819-28. Abstract

18. Metlay JP, Waterer GW, Long AC, et al. Diagnosis and treatment of adults with community-acquired pneumonia. An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-67.Full text  Abstract

19. Torres A, Barberán J, Falguera M, et al. Multidisciplinary guidelines for the management of community-acquired pneumonia [in Spanish]. Med Clin (Barc). 2013 Mar 2;140(5):223.e1-223.e19. Abstract

20. Mandell LA, Marrie TJ, Grossman RF, et al; The Canadian Community-Acquired Pneumonia Working Group. Canadian guidelines for the initial management of community-acquired pneumonia: an evidence-based update by the Canadian Infectious Diseases Society and the Canadian Thoracic Society. Clin Infect Dis. 2000 Aug;31(2):383-421.Full text  Abstract

21. Hogerwerf L, DE Gier B, Baan B, et al. Chlamydia psittaci (psittacosis) as a cause of community-acquired pneumonia: a systematic review and meta-analysis. Epidemiol Infect. 2017 Nov;145(15):3096-105. Abstract

22. Spoorenberg SM, Bos WJ, van Hannen EJ, et al. Chlamydia psittaci: a relevant cause of community-acquired pneumonia in two Dutch hospitals. Neth J Med. 2016 Feb;74(2):75-81. Abstract

23. Cillóniz C, Dominedò C, Nicolini A, et al. PES pathogens in severe community-acquired pneumonia. Microorganisms. 2019 Feb 12;7(2):E49.Full text  Abstract

24. Prina E, Ranzani OT, Polverino E, et al. Risk factors associated with potentially antibiotic-resistant pathogens in community-acquired pneumonia. Ann Am Thorac Soc. 2015 Feb;12(2):153-60. Abstract

25. Jokinen C, Heiskanen L, Juvonen H, et al. Microbial etiology of community-acquired pneumonia in the adult population of 4 municipalities in eastern Finland. Clin Infect Dis. 2001 Apr 15;32(8):1141-54.Full text  Abstract

26. Jennings LC, Anderson TP, Beynon KA, et al. Incidence and characteristics of viral community-acquired pneumonia in adults. Thorax. 2008 Jan;63(1):42-8.Full text  Abstract

27. Burk M, El-Kersh K, Saad M, et al. Viral infection in community-acquired pneumonia: a systematic review and meta-analysis. Eur Respir Rev. 2016 Jun;25(140):178-88.Full text  Abstract

28. Cillóniz C, Dominedò C, Magdaleno D, et al. Pure viral sepsis secondary to community-acquired pneumonia in adults: risk and prognostic factors. J Infect Dis. 2019 Aug 30;220(7):1166-71. Abstract

29. Wunderink RG, Waterer G. Advances in the causes and management of community acquired pneumonia in adults. BMJ. 2017 Jul 10;358:j2471. Abstract

30. Johansson N, Kalin M, Tiveljung-Lindell A, et al. Etiology of community-acquired pneumonia: increased microbiological yield with new diagnostic methods. Clin Infect Dis. 2010 Jan 15;50(2):202-9.Full text  Abstract

31. Alcón A, Fàbregas N, Torres A. Pathophysiology of pneumonia. Clin Chest Med. 2005 Mar;26(1):39-46. Abstract

32. Torres A, Peetermans WE, Viegi G, et al. Risk factors for community-acquired pneumonia in adults in Europe: a literature review. Thorax. 2013 Nov;68(11):1057-65.Full text  Abstract

33. Rumbak MJ. The pathogenesis of ventilator-associated pneumonia. Semin Respir Crit Care Med. 2002 Oct;23(5):427-34. Abstract

34. Dickson RP, Erb-Downward JR, Huffnagle GB. Towards an ecology of the lung: new conceptual models of pulmonary microbiology and pneumonia pathogenesis. Lancet Respir Med. 2014 Mar;2(3):238-46.Full text  Abstract

35. Wu BG, Segal LN. The lung microbiome and its role in pneumonia. Clin Chest Med. 2018 Dec;39(4):677-89. Abstract

36. Man WH, de Steenhuijsen Piters WA, Bogaert D. The microbiota of the respiratory tract: gatekeeper to respiratory health. Nat Rev Microbiol. 2017 May;15(5):259-70. Abstract

37. Cillóniz C, Polverino E, Ewig S, et al. Impact of age and comorbidity on cause and outcome in community-acquired pneumonia. Chest. 2013 Sep;144(3):999-1007. Abstract

38. Polverino E, Dambrava P, Cillóniz C, et al. Nursing home-acquired pneumonia: a 10 year single-centre experience. Thorax. 2010 Apr;65(4):354-9.Full text  Abstract

39. Sund-Levander M, Ortqvist A, Grodzinsky E, et al. Morbidity, mortality and clinical presentation of nursing home-acquired pneumonia in a Swedish population. Scand J Infect Dis. 2003;35(5):306-10. Abstract

40. Molinos L, Clemente MG, Miranda B, et al. Community-acquired pneumonia in patients with and without chronic obstructive pulmonary disease. J Infect. 2009 Jun;58(6):417-24. Abstract

41. Kohlhammer Y, Schwartz M, Raspe H, et al. Risk factors for community acquired pneumonia (CAP): a systematic review [in German]. Dtsch Med Wochenschr. 2005 Feb 25;130(8):381-6. Abstract

42. Garcia-Vidal C, Ardanuy C, Tubau F, et al. Pneumococcal pneumonia presenting with septic shock: host- and pathogen-related factors and outcomes. Thorax. 2010 Jan;65(1):77-81. Abstract

43. Gordin FM, Roediger MP, Girard PM, et al. Pneumonia in HIV-infected persons: increased risk with cigarette smoking and treatment interruption. Am J Respir Crit Care Med. 2008 Sep 15;178(6):630-6.Full text  Abstract

44. Bello S, Menéndez R, Torres A, et al. Tobacco smoking increases the risk for death from pneumococcal pneumonia. Chest. 2014 Oct;146(4):1029-37. Abstract

45. Baskaran V, Murray RL, Hunter A, et al. Effect of tobacco smoking on the risk of developing community acquired pneumonia: a systematic review and meta-analysis. PLoS One. 2019 Jul 18;14(7):e0220204.Full text  Abstract

46. Almirall J, Serra-Prat M, Bolíbar I, et al. Passive smoking at home is a risk factor for community-acquired pneumonia in older adults: a population-based case-control study. BMJ Open. 2014 Jun 13;4(6):e005133.Full text  Abstract

47. Simou E, Britton J, Leonardi-Bee J. Alcohol and the risk of pneumonia: a systematic review and meta-analysis. BMJ Open. 2018 Aug 22;8(8):e022344.Full text  Abstract

48. Samokhvalov AV, Irving HM, Rehm J. Alcohol consumption as a risk factor for pneumonia: a systematic review and meta-analysis. Epidemiol Infect. 2010 Dec;138(12):1789-95. Abstract

49. Cao Y, Liu C, Lin J, et al. Oral care measures for preventing nursing home-acquired pneumonia. Cochrane Database Syst Rev. 2022 Nov 16;11(11):CD012416.Full text  Abstract

50. Abramowitz J, Thakkar P, Isa A, et al. Adverse event reporting for proton pump inhibitor therapy: an overview of systematic reviews. Otolaryngol Head Neck Surg. 2016 Oct;155(4):547-54. Abstract

51. Lambert AA, Lam JO, Paik JJ, et al. Risk of community-acquired pneumonia with outpatient proton-pump inhibitor therapy: a systematic review and meta-analysis. PLoS One. 2015 Jun 4;10(6):e0128004.Full text  Abstract

52. Eom CS, Jeon CY, Lim JW, et al. Use of acid-suppressive drugs and risk of pneumonia: a systematic review and meta-analysis. CMAJ. 2011 Feb 22;183(3):310-9.Full text  Abstract

53. Liapikou A, Cilloniz C, Torres A, et al. Drugs that increase the risk of community-acquired pneumonia: a narrative review. Expert Opin Drug Saf. 2018 Oct;17(10):991-1003. Abstract

54. Almirall J, Bolíbar I, Serra-Prat M, et al. New evidence of risk factors for community-acquired pneumonia: a population-based study. Eur Respir J. 2008 Jun;31(6):1274-84.Full text  Abstract

55. Schnoor M, Klante T, Beckmann M, et al. Risk factors for community-acquired pneumonia in German adults: the impact of children in the household. Epidemiol Infect. 2007 Nov;135(8):1389-97.Full text  Abstract

56. Teepe J, Grigoryan L, Verheij TJ. Determinants of community-acquired pneumonia in children and young adults in primary care. Eur Respir J. 2010 May;35(5):1113-7.Full text  Abstract

57. Cillóniz C, García-Vidal C, Moreno A, et al. Community-acquired bacterial pneumonia in adult HIV-infected patients. Expert Rev Anti Infect Ther. 2018 Jul;16(7):579-88. Abstract

58. Yende S, van der Poll T, Lee M, et al. The influence of pre-existing diabetes mellitus on the host immune response and outcome of pneumonia: analysis of two multicentre cohort studies. Thorax. 2010 Oct;65(10):870-7.Full text  Abstract

59. Kornum JB, Thomsen RW, Riis A, et al. Diabetes, glycemic control, and risk of hospitalization with pneumonia: a population-based case-control study. Diabetes Care. 2008 Aug;31(8):1541-5.Full text  Abstract

60. Kang CI, Song JH, Kim SH, et al. Risk factors and pathogenic significance of bacteremic pneumonia in adult patients with community-acquired pneumococcal pneumonia. J Infect. 2013 Jan;66(1):34-40. Abstract

61. From S, Targowski T. The risk factors of death in community-acquired pneumonia [in Polish]. Pol Merkur Lekarski. 2002 Jun;12(72):455-7. Abstract

62. Chidiac C, Che D, Pires-Cronenberger S, et al. Factors associated with hospital mortality in community-acquired legionellosis in France. Eur Respir J. 2012 Apr;39(4):963-70.Full text  Abstract

63. Fernández J, Navasa M, Gómez J, et al. Bacterial infections in cirrhosis: epidemiological changes with invasive procedures and norfloxacin prophylaxis. Hepatology. 2002 Jan;35(1):140-8.Full text  Abstract

64. Cillóniz C, Ewig S, Polverino E, et al. Pulmonary complications of pneumococcal community-acquired pneumonia: incidence, predictors, and outcomes. Clin Microbiol Infect. 2012 Nov;18(11):1134-42.Full text  Abstract

65. Edelman EJ, Gordon KS, Crothers K, et al. Association of prescribed opioids with increased risk of community-acquired pneumonia among patients with and without HIV. JAMA Intern Med. 2019 Mar 1;179(3):297-304. Abstract

66. Centers for Disease Control and Prevention. Adult immunization schedule by age: recommendations for ages 19 years or older, United States, 2024. Feb 2024 [internet publication].Full text

67. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal vaccine for adults aged ≥19 years: recommendations of the Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep. 2023 Sep 8;72(3):1-39.Full text  Abstract

68. Padhani ZA, Moazzam Z, Ashraf A, et al. Vitamin C supplementation for prevention and treatment of pneumonia. Cochrane Database Syst Rev. 2021 Nov 18;11:CD013134.Full text  Abstract

69. Public Health England. Insufficient evidence for vitamin D preventing or treating ARTIs. Jul 2020 [internet publication].Full text

70. Cheng GS, Crothers K, Aliberti K, et al. Immunocompromised host pneumonia: definitions and diagnostic criteria: an official American Thoracic Society workshop report. Ann Am Thorac Soc. 2023 Mar;20(3):341-53.Full text  Abstract

71. Barbagelata E, Cillóniz C, Dominedò C, et al. Gender differences in community-acquired pneumonia. Minerva Med. 2020 Apr;111(2):153-65. Abstract

72. Niederman MS. Imaging for the management of community-acquired pneumonia: what to do if the chest radiograph is clear. Chest. 2018 Mar;153(3):583-5. Abstract

73. Qaseem A, Etxeandia-Ikobaltzeta I, Mustafa RA, et al. Appropriate use of point-of-care ultrasonography in patients with acute dyspnea in emergency department or inpatient settings: a clinical guideline from the American College of Physicians. Ann Intern Med. 2021 Jul;174(7):985-93.Full text  Abstract

74. Reissig A, Gramegna A, Aliberti S. The role of lung ultrasound in the diagnosis and follow-up of community-acquired pneumonia. Eur J Intern Med. 2012 Jul;23(5):391-7. Abstract

75. Llamas-Álvarez AM, Tenza-Lozano EM, Latour-Pérez J. Accuracy of lung ultrasonography in the diagnosis of pneumonia in adults: systematic review and meta-analysis. Chest. 2017 Feb;151(2):374-82. Abstract

76. Orso D, Guglielmo N, Copetti R. Lung ultrasound in diagnosing pneumonia in the emergency department: a systematic review and meta-analysis. Eur J Emerg Med. 2018 Oct;25(5):312-21. Abstract

77. Gartlehner G, Wagner G, Affengruber L, et al. Point-of-care ultrasonography in patients with acute dyspnea: an evidence report for a clinical practice guideline by the American College of Physicians. Ann Intern Med. 2021 Jul;174(7):967-76.Full text  Abstract

78. Claessens YE, Debray MP, Tubach F, et al. Early chest computed tomography scan to assist diagnosis and guide treatment decision for suspected community-acquired pneumonia. Am J Respir Crit Care Med. 2015 Oct 15;192(8):974-82. Abstract

79. Del Rio-Pertuz G, Gutiérrez JF, Triana AJ, et al. Usefulness of sputum gram stain for etiologic diagnosis in community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2019 May 10;19(1):403.Full text  Abstract

80. Menéndez R, Cavalcanti M, Reyes S, et al. Markers of treatment failure in hospitalised community acquired pneumonia. Thorax. 2008 May;63(5):447-52.Full text  Abstract

81. Woodhead M. New guidelines for the management of adult lower respiratory tract infections. Eur Respir J. 2011 Dec;38(6):1250-1.Full text  Abstract

82. Menéndez R, Sahuquillo-Arce JM, Reyes S, et al. Cytokine activation patterns and biomarkers are influenced by microorganisms in community-acquired pneumonia. Chest. 2012 Jun;141(6):1537-45. Abstract

83. Ugajin M, Yamaki K, Hirasawa N, et al. Predictive values of semi-quantitative procalcitonin test and common biomarkers for the clinical outcomes of community-acquired pneumonia. Respir Care. 2014 Apr;59(4):564-73.Full text  Abstract

84. Sirvent JM, Vidaur L, Gonzalez S, et al. Microscopic examination of intracellular organisms in protected bronchoalveolar mini-lavage fluid for the diagnosis of ventilator-associated pneumonia. Chest. 2003 Feb;123(2):518-23. Abstract

85. Murdoch DR. How recent advances in molecular tests could impact the diagnosis of pneumonia. Expert Rev Mol Diagn. 2016;16(5):533-40. Abstract

86. Evans SE, Jennerich AL, Azar MM, et al. Nucleic acid-based testing for noninfluenza viral pathogens in adults with suspected community-acquired pneumonia. An official American Thoracic Society clinical practice guideline. Am J Respir Crit Care Med. 2021 May1;203(9):1070-87.Full text  Abstract

87. Simundic AM, Bölenius K, Cadamuro J, et al. Joint EFLM-COLABIOCLI recommendation for venous blood sampling. Clin Chem Lab Med. 2018;56(12):2015-38. Abstract

88. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243-50.Full text  Abstract

89. Lim WS, van der Eerden MM, Laing R, et al. Defining community acquired pneumonia severity on presentation to hospital: an international derivation and validation study. Thorax. 2003 May;58(5):377-82.Full text  Abstract

90. Darden DB, Hawkins RB, Larson SD, et al. The clinical presentation and immunology of viral pneumonia and implications for management of coronavirus disease 2019. Crit Care Explor. 2020 Apr;2(4):e0109.Full text  Abstract

91. Struyf T, Deeks JJ, Dinnes J, et al. Signs and symptoms to determine if a patient presenting in primary care or hospital outpatient settings has COVID-19. Cochrane Database Syst Rev. 2022 May 20;(5):CD013665.Full text  Abstract

92. Sadiq Z, Rana S, Mahfoud Z, et al. Systematic review and meta-analysis of chest radiograph (CXR) findings in COVID-19. Clin Imaging. 2021 Dec;80:229-38.Full text  Abstract

93. González-Moraleja J, Sesma P, González C, et al. What is the cost of inappropriate admission of pneumonia patients? [in Spanish]. Arch Bronconeumol. 1999 Jul-Aug;35(7):312-6. Abstract

94. Smith MD, Fee C, et al. Clinical policy: critical issues in the management of adult patients presenting to the emergency department with community-acquired pneumonia. Ann Emerg Med. 2021 Jan;77(1):e1-e57. Abstract

95. España PP, Capelastegui A, Gorordo I, et al. Development and validation of a clinical prediction rule for severe community-acquired pneumonia. Am J Respir Crit Care Med. 2006 Dec 1;174(11):1249-56.Full text  Abstract

96. Charles PG, Wolfe R, Whitby M, et al. SMART-COP: a tool for predicting the need for intensive respiratory or vasopressor support in community-acquired pneumonia. Clin Infect Dis. 2008 Aug 1;47(3):375-84.Full text  Abstract

97. Restrepo MI, Mortensen EM, Rello J, et al. Late admission to the ICU in patients with community-acquired pneumonia is associated with higher mortality. Chest. 2010 Mar;137(3):552-7.Full text  Abstract

98. Brown SM, Jones JP, Aronsky D, et al. Relationships among initial hospital triage, disease progression and mortality in community-acquired pneumonia. Respirology. 2012 Nov;17(8):1207-13.Full text  Abstract

99. Phua J, Ngerng WJ, Lim TK. The impact of a delay in intensive care unit admission for community-acquired pneumonia. Eur Respir J. 2010 Oct;36(4):826-33.Full text  Abstract

100. Aliberti S, Ramirez J, Cosentini R, et al. Low CURB-65 is of limited value in deciding discharge of patients with community-acquired pneumonia. Respir Med. 2011 Nov;105(11):1732-8.Full text  Abstract

101. Sharp AL, Jones JP, Wu I, et al. CURB-65 performance among admitted and discharged emergency department patients with community-acquired pneumonia. Acad Emerg Med. 2016 Apr;23(4):400-5. Abstract

102. Niederman M. In the clinic: community-acquired pneumonia. Ann Intern Med. 2009 Oct 6;151(7):ITC4-2-ITC4. Abstract

103. Halm EA, Teirstein AS. Clinical practice: management of community-acquired pneumonia. N Engl J Med. 2002 Dec 19;347(25):2039-45. Abstract

104. Furuya EY, Lowy FD. Antimicrobial-resistant bacteria in the community setting. Nat Rev Microbiol. 2006 Jan;4(1):36-45. Abstract

105. Lynch JP 3rd, Zhanel GG. Streptococcus pneumoniae: does antimicrobial resistance matter? Semin Respir Crit Care Med. 2009 Apr;30(2):210-38. Abstract

106. Fenoll A, Granizo JJ, Aguilar L, et al. Temporal trends of invasive Streptococcus pneumoniae serotypes and antimicrobial resistance patterns in Spain from 1979 to 2007. J Clin Microbiol. 2009 Apr;47(4):1012-20.Full text  Abstract

107. Dagan R, Klugman KP. Impact of conjugate pneumococcal vaccines on antibiotic resistance. Lancet Infect Dis. 2008 Dec;8(12):785-95. Abstract

108. Aspa J, Rajas O, de Castro FR. Pneumococcal antimicrobial resistance: therapeutic strategy and management in community-acquired pneumonia. Expert Opin Pharmacother. 2008 Feb;9(2):229-41. Abstract

109. O'Driscoll BR, Howard LS, Earis J, et al. British Thoracic Society Guideline for oxygen use in adults in healthcare and emergency settings. BMJ Open Respir Res. 2017;4(1):e000170.Full text  Abstract

110. Naucler P, Strålin K. Routine atypical antibiotic coverage is not necessary in hospitalised patients with non-severe community-acquired pneumonia. Int J Antimicrob Agents. 2016 Aug;48(2):224-5. Abstract

111. Postma DF, van Werkhoven CH, Oosterheert JJ. Community-acquired pneumonia requiring hospitalization: rational decision making and interpretation of guidelines. Curr Opin Pulm Med. 2017 May;23(3):204-10. Abstract

112. File TM Jr, Marrie TJ. Does empiric therapy for atypical pathogens improve outcomes for patients with CAP? Infect Dis Clin North Am. 2013 Mar;27(1):99-114. Abstract

113. File TM Jr, Eckburg PB, Talbot GH, et al. Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point. Int J Antimicrob Agents. 2017 Aug;50(2):247-51. Abstract

114. Eljaaly K, Alshehri S, Aljabri A, et al. Clinical failure with and without empiric atypical bacteria coverage in hospitalized adults with community-acquired pneumonia: a systematic review and meta-analysis. BMC Infect Dis. 2017 Jun 2;17(1):385.Full text  Abstract

115. Rusu A, Munteanu AC, Arbănași EM, et al. Overview of side-effects of antibacterial fluoroquinolones: new drugs versus old drugs, a step forward in the safety profile? Pharmaceutics. 2023 Mar 1;15(3):804.Full text  Abstract

116. Garnacho-Montero J, Barrero-García I, Gómez-Prieto MG, et al. Severe community-acquired pneumonia: current management and future therapeutic alternatives. Expert Rev Anti Infect Ther. 2018 Sep;16(9):667-77. Abstract

117. Uranga A, España PP, Bilbao A, et al. Duration of antibiotic treatment in community-acquired pneumonia: a multicenter randomized clinical trial. JAMA Intern Med. 2016 Sep 1;176(9):1257-65. Abstract

118. Lee RA, Centor RM, Humphrey LL, et al. Appropriate use of short-course antibiotics in common infections: best practice advice from the American College of Physicians. Ann Intern Med. 2021 Jun;174(6):822-7.Full text  Abstract

119. Vaughn VM, Flanders SA, Snyder A, et al. Excess antibiotic treatment duration and adverse events in patients hospitalized with pneumonia: a multihospital cohort study. Ann Intern Med. 2019 Aug 6;171(3):153-63. Abstract

120. Lan SH, Lai CC, Chang SP, et al. Five-day antibiotic treatment for community-acquired bacterial pneumonia: a systematic review and meta-analysis of randomized controlled trials. J Glob Antimicrob Resist. 2020 Dec;23:94-9.Full text  Abstract

121. Dinh A, Ropers J, Duran C, et al. Discontinuing β-lactam treatment after 3 days for patients with community-acquired pneumonia in non-critical care wards (PTC): a double-blind, randomised, placebo-controlled, non-inferiority trial. Lancet. 2021 Mar 27;397(10280):1195-203. Abstract

122. Siemieniuk RA, Meade MO, Alonso-Coello P, et al. Corticosteroid therapy for patients hospitalized with community-acquired pneumonia: a systematic review and meta-analysis. Ann Intern Med. 2015 Oct 6;163(7):519-28. Abstract

123. Bi J, Yang J, Wang Y, Yao C, et al. Efficacy and safety of adjunctive corticosteroids therapy for severe community-acquired pneumonia in adults: an updated systematic review and meta-analysis. PLoS One. 2016 Nov 15;11(11):e0165942.Full text  Abstract

124. Briel M, Spoorenberg SMC, Snijders D, et al. Corticosteroids in patients hospitalized with community-acquired pneumonia: systematic review and individual patient data meta-analysis. Clin Infect Dis. 2018 Jan 18;66(3):346-54. Abstract

125. Stern A, Skalsky K, Avni T, et al. Corticosteroids for pneumonia. Cochrane Database Syst Rev. 2017 Dec 13;12:CD007720.Full text  Abstract

126. Wu WF, Fang Q, He GJ. Efficacy of corticosteroid treatment for severe community-acquired pneumonia: a meta-analysis. Am J Emerg Med. 2018 Feb;36(2):179-84. Abstract

127. Huang J, Guo J, Li H, et al. Efficacy and safety of adjunctive corticosteroids therapy for patients with severe community-acquired pneumonia: a systematic review and meta-analysis. Medicine (Baltimore). 2019 Mar;98(13):e14636.Full text  Abstract

128. Jiang S, Liu T, Hu Y, et al. Efficacy and safety of glucocorticoids in the treatment of severe community-acquired pneumonia: a meta-analysis. Medicine (Baltimore). 2019 Jun;98(26):e16239.Full text  Abstract

129. Aliberti S, Blasi F. Clinical stability versus clinical failure in patients with community-acquired pneumonia. Semin Respir Crit Care Med. 2012 Jun;33(3):284-91. Abstract

130. Menendez R, Torres A. Treatment failure in community-acquired pneumonia. Chest. 2007 Oct;132(4):1348-55. Abstract

131. Schuetz P, Wirz Y, Sager R, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract infections. Cochrane Database Syst Rev. 2017 Oct 12;(10):CD007498.Full text  Abstract

132. Schuetz P, Wirz Y, Sager R, et al. Effect of procalcitonin-guided antibiotic treatment on mortality in acute respiratory infections: a patient level meta-analysis. Lancet Infect Dis. 2018 Jan;18(1):95-107. Abstract

133. Lam SW, Bauer SR, Fowler R, et al. Systematic review and meta-analysis of procalcitonin-guidance versus usual care for antimicrobial management in critically ill patients: focus on subgroups based on antibiotic initiation, cessation, or mixed strategies. Crit Care Med. 2018 May;46(5):684-90. Abstract

134. Huang DT, Yealy DM, Filbin MR, et al. Procalcitonin-guided use of antibiotics for lower respiratory tract infection. N Engl J Med. 2018 Jul 19;379(3):236-49.Full text  Abstract

135. Schuetz P, Bolliger R, Merker M, et al. Procalcitonin-guided antibiotic therapy algorithms for different types of acute respiratory infections based on previous trials. Expert Rev Anti Infect Ther. 2018 Jul;16(7):555-64. Abstract

136. Centers for Disease Control and Prevention. Valley fever: testing algorithm for coccidioidomycosis. May 2024 [internet publication].Full text

137. Centers for Disease Control and Prevention. Testing algorithm for histoplasmosis​. May 2024 [internet publication].Full text

138. Lloyd M, Karahalios A, Janus E, et al. Effectiveness of a bundled intervention including adjunctive corticosteroids on outcomes of hospitalized patients with community-acquired pneumonia: a stepped-wedge randomized clinical trial. JAMA Intern Med. 2019 Aug 1;179(8):1052-60. Abstract

139. Soar J, Böttiger BW, Carli P, et al. European Resuscitation Council guidelines 2021: adult advanced life support. Resuscitation. 2021 Apr;161:115-51.Full text  Abstract

140. Colquhoun MC, Handley AJ, Evans TR. ABC of resuscitation. 5th ed. London: BMJ Publishing Group; 2004.

141. Chrimes N, Higgs A, Hagberg CA, et al. Preventing unrecognised oesophageal intubation: a consensus guideline from the Project for Universal Management of Airways and international airway societies. Anaesthesia. 2022 Dec;77(12):1395-415.Full text  Abstract

142. Kusminsky RE. Complications of central venous catheterization. J Am Coll Surg. 2007 Apr;204(4):681-96. Abstract

143. McGee DC, Gould MK. Preventing complications of central venous catheterization. N Engl J Med. 2003 Mar 20;348(12):1123-33.Full text  Abstract

144. Smith RN, Nolan JP. Central venous catheters. BMJ. 2013 Nov 11;347:f6570.Full text  Abstract

145. Reich DL. Monitoring in anesthesia and perioperative care. Cambridge: Cambridge University Press; 2011.

146. Abbott Northwestern Hospital Internal Medicine Residency. Internal jugular central venous line. 2022 [internet publication].Full text

147. Bishop L, Dougherty L, Bodenham A, et al. Guidelines on the insertion and management of central venous access devices in adults. Int J Lab Hematol. 2007 Aug;29(4):261-78. Abstract

148. Practice guidelines for central venous access 2020: an updated report by the American Society of Anesthesiologists Task Force on Central Venous Access. Anesthesiology. 2020 Jan;132(1):8-43.Full text  Abstract

149. Fletcher SJ, Bodenham AR. Safe placement of central venous catheters: where should the tip of the catheter lie? Br J Anaesth. 2000 Aug;85(2):188-91. Abstract

150. Gibson F, Bodenham A. Misplaced central venous catheters: applied anatomy and practical management. Br J Anaesth. 2013 Mar;110(3):333-46.Full text  Abstract

151. Schuster M, Nave H, Piepenbrock S, et al. The carina as a landmark in central venous catheter placement. Br J Anaesth. 2000 Aug;85(2):192-4. Abstract

152. Webster J, Osborne S, Rickard CM, et al. Clinically-indicated replacement versus routine replacement of peripheral venous catheters. Cochrane Database Syst Rev. 2019 Jan 23;(1):CD007798.Full text  Abstract

153. Dillon C, Guarascio AJ, Covvey JR. Lefamulin: a promising new pleuromutilin antibiotic in the pipeline. Expert Rev Anti Infect Ther. 2019 Jan;17(1):5-15. Abstract

154. Paukner S, Gelone SP, Arends SJR, et al. Antibacterial activity of lefamulin against pathogens most commonly causing community-acquired bacterial pneumonia: SENTRY Antimicrobial Surveillance Program (2015-2016). Antimicrob Agents Chemother. 2019 Mar 27;63(4):e02161-18.Full text  Abstract

155. Veve MP, Wagner JL. Lefamulin: review of a promising novel pleuromutilin antibiotic. Pharmacotherapy. 2018 Sep;38(9):935-46. Abstract

156. File TM Jr, Goldberg L, Das A, et al. Efficacy and safety of IV-to-oral lefamulin, a pleuromutilin antibiotic, for treatment of community-acquired bacterial pneumonia: the phase 3 LEAP 1 trial. Clin Infect Dis. 2019 Nov 13;69(11):1856-67.Full text  Abstract

157. Alexander E, Goldberg L, Das AF, et al. Oral lefamulin vs moxifloxacin for early clinical response among adults with community-acquired bacterial pneumonia: the LEAP 2 randomized clinical trial. JAMA. 2019 Nov 5;322(17):1661-71. Abstract

158. Chahine EB, Sucher AJ. Lefamulin: the first systemic pleuromutilin antibiotic. Ann Pharmacother. 2020 Dec;54(12):1203-14. Abstract

159. ClinicalTrials.gov. Study to compare delafloxacin to moxifloxacin for the treatment of adults with community-acquired bacterial pneumonia (DEFINE-CABP). Feb 2020 [internet publication].Full text

160. Stets R, Popescu M, Gonong JR, et al. Omadacycline for community-acquired bacterial pneumonia. N Engl J Med. 2019 Feb 7;380(6):517-27.Full text  Abstract

161. Nicholson SC, Welte T, File TM Jr, et al. A randomised, double-blind trial comparing ceftobiprole medocaril with ceftriaxone with or without linezolid for the treatment of patients with community-acquired pneumonia requiring hospitalisation. Int J Antimicrob Agents. 2012 Mar;39(3):240-6. Abstract

162. Chang SP, Lee HZ, Lai CC, et al. The efficacy and safety of nemonoxacin compared with levofloxacin in the treatment of community-acquired pneumonia: a systemic review and meta-analysis of randomized controlled trials. Infect Drug Resist. 2019 Feb 14;12:433-8.Full text  Abstract

163. Oldach D, Clark K, Schranz J, et al. Randomized, double-blind, multicenter phase 2 study comparing the efficacy and safety of oral solithromycin (CEM-101) to those of oral levofloxacin in the treatment of patients with community-acquired bacterial pneumonia. Antimicrob Agents Chemother. 2013 Jun;57(6):2526-34.Full text  Abstract

164. File TM Jr, Rewerska B, Vucinic-Mihailovic V, et al. SOLITAIRE-IV: a randomized, double-blind, multicenter study comparing the efficacy and safety of intravenous-to-oral solithromycin to intravenous-to-oral moxifloxacin for treatment of community-acquired bacterial pneumonia. Clin Infect Dis. 2016 Oct 15;63(8):1007-16.Full text  Abstract

165. Grudzinska FS, Dosanjh DP, Parekh D, et al. Statin therapy in patients with community-acquired pneumonia. Clin Med (Lond). 2017 Oct;17(5):403-7.Full text  Abstract

166. Wang ST, Sun XF. Role of statins in treatment and prevention of community-acquired pneumonia: a meta-analysis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2018 Feb 28;40(1):30-40. Abstract

167. National Institute for Health and Care Excellence. Pneumonia in adults: diagnosis and management. Oct 2023 [internet publication].Full text

168. National Institute for Health and Care Excellence. Pneumonia (community-acquired): antimicrobial prescribing. Sep 2019 [internet publication].Full text

169. Luna HI, Pankey G. The utility of blood culture in patients with community-acquired pneumonia. Ochsner J. 2001 Apr;3(2):85-93.Full text  Abstract

170. Torres A, Cillóniz C, Ferrer M, et al. Bacteraemia and antibiotic-resistant pathogens in community acquired pneumonia: risk and prognosis. Eur Respir J. 2015 May;45(5):1353-63. Abstract

171. Sligl WI, Marrie TJ. Severe community-acquired pneumonia. Crit Care Clin. 2013 Jul;29(3):563-601. Abstract

172. Melzer M, Welch C. 30-day mortality in UK patients with bacteraemic community-acquired pneumonia. Infection. 2013 Oct;41(5):1005-11. Abstract

173. Jasti H, Mortensen EM, Obrosky DS, et al. Causes and risk factors for rehospitalization of patients hospitalized with community-acquired pneumonia. Clin Infect Dis. 2008 Feb 15;46(4):550-6.Full text  Abstract

174. Capelastegui A, España Yandiola PP, Quintana JM, et al. Predictors of short-term rehospitalization following discharge of patients hospitalized with community-acquired pneumonia. Chest. 2009 Oct;136(4):1079-85. Abstract

175. Viasus D, Del Rio-Pertuz G, Simonetti AF, et al. Biomarkers for predicting short-term mortality in community-acquired pneumonia: a systematic review and meta-analysis. J Infect. 2016 Mar;72(3):273-82. Abstract

176. Jiang J, Yang J, Jin Y, et al. Role of qSOFA in predicting mortality of pneumonia: a systematic review and meta-analysis. Medicine (Baltimore). 2018 Oct;97(40):e12634.Full text  Abstract

177. Cillóniz C, Dominedò C, Ielpo A, et al. Risk and prognostic factors in very old patients with sepsis secondary to community-acquired pneumonia. J Clin Med. 2019 Jul 2;8(7):E961.Full text  Abstract

178. Cilloniz C, Ferrer M, Liapikou A, et al. Acute respiratory distress syndrome in mechanically ventilated patients with community-acquired pneumonia. Eur Respir J. 2018 Mar 29;51(3):1702215.Full text  Abstract

179. Corrales-Medina VF, Suh KN, Rose G, et al. Cardiac complications in patients with community-acquired pneumonia: a systematic review and meta-analysis of observational studies. PLoS Med. 2011 Jun;8(6):e1001048.Full text  Abstract

180. Becker T, Moldoveanu A, Cukierman T, et al. Clinical outcomes associated with the use of subcutaneous insulin-by-glucose sliding scales to manage hyperglycemia in hospitalized patients with pneumonia. Diabetes Res Clin Pract. 2007 Dec;78(3):392-7. Abstract

181. Ramirez J, Aliberti S, Mirsaeidi M, et al. Acute myocardial infarction in hospitalized patients with community-acquired pneumonia. Clin Infect Dis. 2008 Jul 15;47(2):182-7.Full text  Abstract

182. Corrales-Medina VF, Serpa J, Rueda AM, et al. Acute bacterial pneumonia is associated with the occurrence of acute coronary syndromes. Medicine (Baltimore). 2009 May;88(3):154-9. Abstract

183. Light RW, Girard WM, Jenkinson SG, et al. Parapneumonic effusions. Am J Med. 1980 Oct;69(4):507-12. Abstract

184. Taryle DA, Potts DE, Sahn SA. The incidence and clinical correlates of parapneumonic effusions in pneumococcal pneumonia. Chest. 1978 Aug;74(2):170-3. Abstract

185. Menéndez R, Torres A, Zalacaín R, et al. Risk factors of treatment failure in community acquired pneumonia: implications for disease outcome. Thorax. 2004 Nov;59(11):960-5.Full text  Abstract

186. Tsai YF, Ku YH. Necrotizing pneumonia: a rare complication of pneumonia requiring special consideration. Curr Opin Pulm Med. 2012 May;18(3):246-52. Abstract

Comorbidities Manager reference articles

187. US Preventive Services Task Force, Krist AH, Davidson KW, et al. Interventions for tobacco smoking cessation in adults, including pregnant persons: US Preventive Services Task Force recommendation statement. JAMA. 2021 Jan 19;325(3):265-79.Full text  Abstract

188. Centers for Disease Control and Prevention (CDC). A practical guide to help your patients quit using tobacco. [internet publication].Full text

189. Fiore MC, Jaén CR, Baker TB, et al. Treating tobacco use and dependence: 2008 update. Clinical practice guideline. Rockville, MD: US Department of Health and Human Services Public Health Service; May 2008 [internet publication].Full text

190. United States Public Health Service Office of the Surgeon General, National Center for Chronic Disease Prevention and Health Promotion (US) Office on Smoking and Health. Smoking cessation: a report of the Surgeon General. Washington, DC: US Department of Health and Human Services; 2020 [internet publication].Full text  Abstract

191. Centers for Disease Control and Prevention (CDC) - You can help your patients quit tobacco. May 2019 [internet publication].Full text

192. Perret J, Yip SWS, Idrose NS, et al. Undiagnosed and 'overdiagnosed' COPD using postbronchodilator spirometry in primary healthcare settings: a systematic review and meta-analysis. BMJ Open Respir Res. 2023 Apr;10(1):e001478.Full text  Abstract

193. Ezekowitz JA, O'Meara E, McDonald MA, et al. 2017 Comprehensive update of the Canadian Cardiovascular Society Guidelines for the management of heart failure. Can J Cardiol. 2017 Nov;33(11):1342-433.Full text  Abstract

194. Burgos J, Luján M, Larrosa MN, et al. Risk factors for respiratory failure in pneumococcal pneumonia: the importance of pneumococcal serotypes. Eur Respir J. 2014 Feb;43(2):545-53.Full text  Abstract

195. Blonde L, Umpierrez GE, Reddy SS, et al. American Association of Clinical Endocrinology clinical practice guideline: developing a diabetes mellitus comprehensive care plan - 2022 update. Endocr Pract. 2022 Oct;28(10):923-1049.Full text  Abstract

196. Su G, Iwagami M, Qin X, et al. Kidney disease and mortality in patients with respiratory tract infections: a systematic review and meta-analysis. Clin Kidney J. 2021 Feb;14(2):602-11.Full text  Abstract

197. Yu Y, Liu W, Jiang HL, et al. Pneumonia is associated with increased mortality in hospitalized COPD patients: a systematic review and meta-analysis. Respiration. 2021;100(1):64-76. Abstract

198. Fang YY, Ni JC, Wang Y, et al. Risk factors for hospital readmissions in pneumonia patients: a systematic review and meta-analysis. World J Clin Cases. 2022 Apr 26;10(12):3787-800.Full text  Abstract

199. Manabe T, Fujikura Y, Mizukami K, et al. Pneumonia-associated death in patients with dementia: a systematic review and meta-analysis. PLoS One. 2019;14(3):e0213825.Full text  Abstract

200. Rao A, Suliman A, Vuik S, et al. Outcomes of dementia: Systematic review and meta-analysis of hospital administrative database studies. Arch Gerontol Geriatr. 2016 Sep-Oct;66:198-204. Abstract

201. Foley NC, Affoo RH, Martin RE. A systematic review and meta-analysis examining pneumonia-associated mortality in dementia. Dement Geriatr Cogn Disord. 2015;39(1-2):52-67.Full text  Abstract

202. Kundi H, Wadhera RK, Strom JB, et al. Association of frailty with 30-Day outcomes for acute myocardial infarction, heart failure, and pneumonia among elderly adults. JAMA Cardiol. 2019 Nov 1;4(11):1084-91.Full text  Abstract

203. Fine MJ, Auble TE, Yealy DM, et al. A prediction rule to identify low-risk patients with community-acquired pneumonia. N Engl J Med. 1997 Jan 23;336(4):243-50.Full text  Abstract

204. Rockwood K, Song X, MacKnight C, et al. A global clinical measure of fitness and frailty in elderly people. CMAJ. 2005 Aug 30;173(5):489-95.Full text  Abstract

205. Church S, Rogers E, Rockwood K, et al. A scoping review of the Clinical Frailty Scale. BMC Geriatr. 2020 Oct 7;20(1):393.Full text  Abstract

206. Rockwood K, Theou O. Using the clinical frailty ccale in allocating scarce health care resources. Can Geriatr J. 2020 Sep;23(3):210-5.Full text  Abstract

207. Miller RK, Young M, Chippendale R, et al. Using the Geriatric 5Ms to teach structural and social determinants of health. J Am Geriatr Soc. 2023 Dec;71(12):3967-72. Abstract

208. Molnar F, Frank CC. Optimizing geriatric care with the GERIATRIC 5Ms. Can Fam Physician. 2019 Jan;65(1):39.Full text  Abstract

209. Tinetti M, Huang A, Molnar F. The Geriatrics 5M's: a new way of communicating what we do. J Am Geriatr Soc. 2017 Sep;65(9):2115.Full text  Abstract

210. Jamshed N, Gangavati A. Prioritizing the 5Ms in geriatric care: a holistic approach to care of the older adult. Am Fam Physician. 2024 Jun;109(6):498-500.Full text  Abstract

211. Watson KE, Dhaliwal K, Robertshaw S, et al. Consensus recommendations for sick day medication guidance for people with diabetes, kidney, or cardiovascular disease: a modified Delphi process. Am J Kidney Dis. 2023 May;81(5):564-74.Full text  Abstract

212. Umpierrez GE, Davis GM, ElSayed NA, et al. Hyperglycaemic crises in adults with diabetes: a consensus report. Diabetologia. 2024 Aug;67(8):1455-79.Full text  Abstract

213. Centers for Disease Control and Prevention. Managing sick days. May 2024 [internet publication].Full text

214. American Diabetes Association Professional Practice Committee. 6. Glycemic goals and hypoglycemia: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S111-25.Full text  Abstract

215. Primary Care Diabetes Society. How to advise on sick day rules. Apr 2020 [internet publication].Full text

216. American Diabetes Association Professional Practice Committee. 9. Pharmacologic approaches to glycemic treatment: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S158-78.Full text  Abstract

217. Diabetes Canada Clinical Practice Guidelines Expert Committee; Lipscombe L, Booth G, Butalia S, et al. Pharmacologic glycemic management of type 2 diabetes in adults. Can J Diabetes. 2018 Apr;42 Suppl 1:S88-103.Full text  Abstract

218. Davies MJ, Aroda VR, Collins BS, et al. Management of hyperglycemia in type 2 diabetes, 2022: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2022 Nov 1;45(11):2753-86.Full text  Abstract

219. Peters AL, Buschur EO, Buse JB, et al. Euglycemic diabetic ketoacidosis: a potential complication of treatment with sodium-glucose cotransporter 2 inhibition. Diabetes Care. 2015 Sep;38(9):1687-93.Full text  Abstract

220. US Food and Drug Administration. FDA revises labels of SGLT2 inhibitors for diabetes to include warnings about too much acid in the blood and serious urinary tract infections. March 2022 [internet publication].Full text

221. American Diabetes Association Professional Practice Committee. 13. Older adults: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S244-57.Full text  Abstract

222. Primary Care Diabetes Society. How to advise on sick day rules. April 2020 [internet publication].Full text

223. Cesari M, Calvani R, Marzetti E. Frailty in older persons. Clin Geriatr Med. 2017 Aug;33(3):293-303. Abstract

224. Rockwood K, British Geriatrics Society. Silver book II: frailty. February 2021 [internet publication].Full text

225. Falk Erhag H, Guðnadóttir G, Alfredsson J, et al. The association between the clinical frailty scale and adverse health outcomes in older adults in acute cinical settings - a systematic review of the literature. Clin Interv Aging. 2023 Feb 18:18:249-61.Full text  Abstract

226. Quinn TJ, Mooijaart SP, Gallacher K, et al. Acute care assessment of older adults living with frailty. BMJ. 2019 Jan 31;364:l13. Abstract

227. Anderson WG, Berlinger N, Ragland J et al. Hospital-based prognosis and goals of care discussions with seriously ill patients: a pathway to integrate a key primary palliative care process into the workflow of hospitalist physicians and their teams. Society of Hospital Medicine and The Hastings Center, 2017 [internet publication].Full text

228. Secunda K, Wirpsa MJ, Neely KJ, et al. Use and meaning of "goals of care" in the healthcare literature: a systematic review and qualitative discourse analysis. J Gen Intern Med. 2020 May;35(5):1559-66.Full text  Abstract

229. American College of Surgeons. Best practice guidelines: geriatric trauma management. 2023 [internet publication].Full text

230. Boyd C, Smith CD, Masoudi FA, et al. Decision making for older adults with multiple chronic conditions: executive summary for the American Geriatrics Society guiding principles on the care of older adults with multimorbidity. J Am Geriatr Soc. 2019 Apr;67(4):665-73. Abstract

231. Appelbaum PS. Clinical practice. Assessment of patients' competence to consent to treatment. N Engl J Med. 2007 Nov 1;357(18):1834-40. Abstract

232. Sulmasy LS, Bledsoe TA, ACP Ethics, Professionalism and Human Rights Committee. American College of Physicians ethics manual: seventh edition. Ann Intern Med. 2019 Jan 15;170(2_suppl):S1-32.Full text  Abstract

233. Barstow C, Shahan B, Roberts M. Evaluating medical decision-making capacity in practice. Am Fam Physician. 2018 Jul 1;98(1):40-6.Full text  Abstract

234. Farrell TW, Widera E, Rosenberg L, et al. AGS position statement: making medical treatment decisions for unbefriended older adults. J Am Geriatr Soc. 2017 Jan;65(1):14-5.Full text  Abstract

235. Pope TM, Bennett J, Carson SS, et al. Making medical treatment decisions for unrepresented patients in the ICU. An official American Thoracic Society/American Geriatrics Society policy statement. Am J Respir Crit Care Med. 2020 May 15;201(10):1182-92.Full text  Abstract

236. Al-Halawani R, Charlton PH, Qassem M, et al. A review of the effect of skin pigmentation on pulse oximeter accuracy. Physiol Meas. 2023 Jun 1;44(5):05TR01.Full text  Abstract

237. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. 2024 [internet publication].Full text

238. O'Driscoll BR, Howard LS, Earis J, et al. BTS guideline for oxygen use in adults in healthcare and emergency settings. Thorax. 2017 Jun;72(suppl 1):ii1-90.Full text  Abstract

239. Saberian L, Sharif M, Aarabi M, et al. Arterial versus venous blood gas analysis comparisons, appropriateness, and alternatives in different acid/base clinical settings: a systematic review. Cureus. 2023 Jul;15(7):e41707.Full text  Abstract

240. Csoma B, Vulpi MR, Dragonieri S, et al. Hypercapnia in COPD: causes, consequences, and therapy. J Clin Med. 2022 Jun 2;11(11):3180.Full text  Abstract

241. Chu DK, Kim LH, Young PJ, et al. Mortality and morbidity in acutely ill adults treated with liberal versus conservative oxygen therapy (IOTA): a systematic review and meta-analysis. Lancet. 2018 Apr 28;391(10131):1693-705. Abstract

242. Siemieniuk RAC, Chu DK, Kim LH, et al. Oxygen therapy for acutely ill medical patients: a clinical practice guideline. BMJ. 2018 Oct 24;363:k4169.Full text  Abstract

243. Veenstra P, Veeger NJGM, Koppers RJH, et al. High-flow nasal cannula oxygen therapy for admitted COPD-patients. A retrospective cohort study. PLoS One. 2022 Oct 5;17(10):e0272372.Full text  Abstract

244. Du Y, Zhang H, Ma Z, et al. High-flow nasal oxygen versus noninvasive ventilation in acute exacerbation of chronic obstructive pulmonary disease patients: a meta-analysis of randomized controlled trials. Can Respir J. 2023 Jun 30:2023:7707010.Full text  Abstract

245. Xu Z, Zhu L, Zhan J, et al. The efficacy and safety of high-flow nasal cannula therapy in patients with COPD and type II respiratory failure: a meta-analysis and systematic review. Eur J Med Res. 2021 Oct 14;26(1):122.Full text  Abstract

246. Global Initiative for Asthma. Global strategy for asthma management and prevention. 2024 [internet publication].Full text

247. Panchal AR, Bartos JA, Cabañas JG, et al. Part 3: Adult basic and advanced life support: 2020 American Heart Association guidelines for cardiopulmonary resuscitation and emergency cardiovascular care. Circulation. 2020 Oct 20;142(16 suppl 2):S366-468.Full text  Abstract

248. Rodrigo GJ, Rodrigo C, Hall JB. Acute asthma in adults: a review. Chest. 2004 Mar;125(3):1081-102. Abstract

249. Vasileiadis I, Alevrakis E, Ampelioti S, et al. Acid-base disturbances in patients with asthma: a literature review and comments on their pathophysiology. J Clin Med. 2019 Apr 25;8(4):563.Full text  Abstract

250. Elhassan MG, Chao PW, Curiel A. The conundrum of volume status assessment: revisiting current and future tools available for physicians at the bedside. Cureus. 2021 May 26;13(5):e15253.Full text  Abstract

251. Rezayat T, Barjaktarevic I, Mecham I, et al. Early protocolized bedside ultrasound in shock: renal function improvements and other lessons learned. Int J Crit Care Emerg Med. 2018 Oct 6;4(2):046.Full text

252. Seif D, Perera P, Mailhot T, et al. Bedside ultrasound in resuscitation and the rapid ultrasound in shock protocol. Crit Care Res Pract. 2012;2012:503254.Full text  Abstract

253. American Institute of Ultrasound in Medicine. The AIUM practice parameter for the performance of the Extended Focused Assessment With Sonography for Trauma (EFAST). J Ultrasound Med. 2023 Apr;42(4):E1-7.Full text  Abstract

254. American College of Emergency Physicians. Emergency ultrasound imaging criteria compendium. American College of Emergency Physicians. Ann Emerg Med. 2006 Oct;48(4):487-510.Full text  Abstract

255. Verbrugge FH, Grieten L, Mullens W. Management of the cardiorenal syndrome in decompensated heart failure. Cardiorenal Med. 2014 Dec;4(3-4):176-88.Full text  Abstract

256. Hollenberg SM, Warner Stevenson L, Ahmad T, et al. 2019 ACC expert consensus decision pathway on risk assessment, management, and clinical trajectory of patients hospitalized with heart failure: a report of the American College of Cardiology Solution Set Oversight Committee. J Am Coll Cardiol. 2019 Oct 15;74(15):1966-2011.Full text  Abstract

257. Kanwar MK, Billia F, Randhawa V, et al. Heart failure related cardiogenic shock: an ISHLT consensus conference content summary. J Heart Lung Transplant. 2024 Feb;43(2):189-203.Full text  Abstract

258. Shenvi C, Kennedy M, Austin CA, et al. Managing delirium and agitation in the older emergency department patient: the ADEPT tool. Ann Emerg Med. 2020 Feb;75(2):136-45.Full text  Abstract

259. Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005 Apr;53(4):695-9. Abstract

260. Canadian Geriatrics Society. Update: Public launch of the geriatric 5Ms. 2017 [internet publication].Full text

261. Devlin JW, Skrobik Y, Gélinas C, et al. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU. Crit Care Med. 2018 Sep;46(9):e825-73.Full text  Abstract

262. Inouye SK, Schlesinger MJ, Lydon TJ. Delirium: a symptom of how hospital care is failing older persons and a window to improve quality of hospital care. Am J Med. 1999 May;106(5):565-73.Full text  Abstract

263. Han JH, Wilson A, Vasilevskis EE, et al. Diagnosing delirium in older emergency department patients: validity and reliability of the delirium triage screen and the brief confusion assessment method. Ann Emerg Med. 2013 Nov;62(5):457-65. Abstract

264. American College of Emergency Physicians, American Geriatrics Society, Emergency Nurses Association, et al. Geriatric emergency department guidelines. Ann Emerg Med. 2014 May;63(5):e7-25.Full text  Abstract

265. Inouye SK, van Dyck CH, Alessi CA, et al. Clarifying confusion: the confusion assessment method. A new method for detection of delirium. Ann Intern Med. 1990 Dec 15;113(12):941-8. Abstract

266. Wei LA, Fearing MA, Sternberg EJ, et al. The Confusion Assessment Method: a systematic review of current usage. J Am Geriatr Soc. 2008 May;56(5):823-30. Abstract

267. Ely EW, Margolin R, Francis J, et al. Evaluation of delirium in critically ill patients: validation of the Confusion Assessment Method for the Intensive Care Unit (CAM-ICU). Crit Care Med. 2001 Jul;29(7):1370-9. Abstract

268. Bergeron N, Dubois MJ, Dumont M, et al. Intensive Care Delirium Screening Checklist: evaluation of a new screening tool. Intensive Care Med. 2001 May;27(5):859-64. Abstract

269. National Institute for Health and Care Excellence. Delirium: prevention, diagnosis and management in hospital and long-term care. January 2023 [internet publication].Full text

270. Inouye SK, Bogardus ST Jr, Baker DI, et al. The Hospital Elder Life Program: a model of care to prevent cognitive and functional decline in older hospitalized patients. Hospital Elder Life Program. J Am Geriatr Soc. 2000 Dec;48(12):1697-706. Abstract

271. Hshieh TT, Yang T, Gartaganis SL, et al. Hospital Elder Life Program: systematic review and meta-analysis of effectiveness. Am J Geriatr Psychiatry. 2018 Oct;26(10):1015-33. Abstract

272. Hshieh TT, Yue J, Oh E, et al. Effectiveness of multicomponent nonpharmacological delirium interventions: a meta-analysis. JAMA Intern Med. 2015 Apr;175(4):512-20.Full text  Abstract

273. Mohanty S, Rosenthal RA, Russell MM, et al. Optimal perioperative management of the geriatric patient: a best practices guideline from the American College of Surgeons NSQIP and the American Geriatrics Society. J Am Coll Surg. 2016 May;222(5):930-47. Abstract

274. American Geriatrics Society Expert Panel on Postoperative Delirium in Older Adults. American Geriatrics Society abstracted clinical practice guideline for postoperative delirium in older adults. J Am Geriatr Soc. 2015 Jan;63(1):142-50. Abstract

275. White S, Griffiths R, Baxter M, et al. Guidelines for the peri-operative care of people with dementia: guidelines from the Association of Anaesthetists. Anaesthesia. 2019 Mar;74(3):357-72.Full text  Abstract

276. Inouye SK, Kosar CM, Tommet D, et al. The CAM-S: development and validation of a new scoring system for delirium severity in 2 cohorts. Ann Intern Med. 2014 Apr 15;160(8):526-33.Full text  Abstract

277. Burton JK, Craig L, Yong SQ, et al. Non-pharmacological interventions for preventing delirium in hospitalised non-ICU patients. Cochrane Database Syst Rev. 2021 Nov 26;(11):CD013307.Full text  Abstract

278. Peden CJ, Miller TR, Deiner SG, et al. Improving perioperative brain health: an expert consensus review of key actions for the perioperative care team. Br J Anaesth. 2021 Feb;126(2):423-432.Full text  Abstract

279. The 2023 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2023 updated AGS Beers Criteria® for potentially inappropriate medication use in older adults. J Am Geriatr Soc. 2023 Jul;71(7):2052-81.Full text  Abstract

280. Nikooie R, Neufeld KJ, Oh ES, et al. Antipsychotics for treating delirium in hospitalized adults: a systematic review. Ann Intern Med. 2019 Oct 1;171(7):485-95.Full text  Abstract

281. Mühlbauer V, Möhler R, Dichter MN, et al. Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia. Cochrane Database Syst Rev. 2021 Dec 17;(12):CD013304.Full text  Abstract

282. Yunusa I, Alsumali A, Garba AE, et al. Assessment of reported comparative effectiveness and safety of atypical antipsychotics in the treatment of behavioral and psychological symptoms of dementia: a network meta-analysis. JAMA Netw Open. 2019 Mar 1;2(3):e190828.Full text  Abstract

283. Van Leeuwen E, Petrovic M, van Driel ML, et al. Withdrawal versus continuation of long-term antipsychotic drug use for behavioural and psychological symptoms in older people with dementia. Cochrane Database Syst Rev. 2018 Apr 1;(3):CD007726.Full text  Abstract

284. Shen WK, Sheldon RS, Benditt DG, et al. 2017 ACC/AHA/HRS guideline for the evaluation and management of patients with syncope: a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society. J Am Coll Cardiol. 2017 Aug 1;70(5):e39-110.Full text  Abstract

285. Freeman R, Wieling W, Axelrod FB, et al. Consensus statement on the definition of orthostatic hypotension, neurally mediated syncope and the postural tachycardia syndrome. Clin Auton Res. 2011 Apr;21(2):69-72. Abstract

286. Griffin M, Rao VS, Ivey-Miranda J, et al. Empagliflozin in heart failure: diuretic and cardiorenal effects. Circulation. 2020 Sep 15;142(11):1028-39.Full text  Abstract

287. American Diabetes Association Professional Practice Committee. 16. Diabetes care in the hospital: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S295-306.Full text  Abstract

288. Korytkowski MT, Muniyappa R, Antinori-Lent K, et al. Management of hyperglycemia in hospitalized adult patients in non-critical care settings: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2022 Jul 14;107(8):2101-28.Full text  Abstract

289. Grunberger G, Sherr J, Allende M, et al. American Association of Clinical Endocrinology clinical practice guideline: the use of advanced technology in the management of persons with diabetes mellitus. Endocr Pract. 2021 Jun;27(6):505-37.Full text  Abstract

290. Galindo RJ, Umpierrez GE, Rushakoff RJ, et al. Continuous glucose monitors and automated insulin dosing systems in the hospital consensus guideline. J Diabetes Sci Technol. 2020 Nov;14(6):1035-64.Full text  Abstract

291. Avari P, Lumb A, Flanagan D, et al. Insulin pumps and hybrid close loop systems within hospital: a scoping review and practical guidance from the Joint British Diabetes Societies for Inpatient Care. J Diabetes Sci Technol. 2023 May;17(3):625-34.Full text  Abstract

292. Umapathysivam MM, Gunton J, Stranks SN, et al. Euglycemic ketoacidosis in two patients without diabetes after introduction of sodium-glucose cotransporter 2 inhibitor for heart failure with reduced ejection fraction. Diabetes Care. 2024 Jan 1;47(1):140-3.Full text  Abstract

293. Honarmand K, Sirimaturos M, Hirshberg EL, et al. Society of Critical Care Medicine guidelines on glycemic control for critically ill children and adults 2024. Crit Care Med. 2024 Apr 1;52(4):e161-81.Full text  Abstract

294. Joint British Diabetes Societies for Inpatient Care. The use of variable rate intravenous insulin infusion (VRIII) in medical inpatients. October 2014 [internet publication].Full text

295. Lim Y, Ohn JH, Jeong J, et al. Effect of the concomitant use of subcutaneous basal insulin and intravenous insulin infusion in the treatment of severe hyperglycemic patients. Endocrinol Metab (Seoul). 2022 Jun;37(3):444-54.Full text  Abstract

296. Thammakosol K, Sriphrapradang C. Effectiveness and safety of early insulin glargine administration in combination with continuous intravenous insulin infusion in the management of diabetic ketoacidosis: a randomized controlled trial. Diabetes Obes Metab. 2023 Mar;25(3):815-22. Abstract

297. Kidney Disease: Improving Global Outcomes (KDIGO) Acute Kidney Injury Work Group. KDIGO clinical practice guideline for acute kidney injury. Kidney Int Suppl. 2012 Mar;2(1):1-138.Full text

298. Grau AJ, Urbanek C, Palm F. Common infections and the risk of stroke. Nat Rev Neurol. 2010 Dec;6(12):681-94. Abstract

299. Elkind MSV, Boehme AK, Smith CJ, et al. Infection as a Stroke risk factor and determinant of outcome after stroke. Stroke. 2020 Oct;51(10):3156-68.Full text  Abstract

300. Eigenbrodt ML, Rose KM, Couper DJ, et al. Orthostatic hypotension as a risk factor for stroke: the atherosclerosis risk in communities (ARIC) study, 1987-1996. Stroke. 2000 Oct;31(10):2307-13.Full text  Abstract

301. Winstein CJ, Stein J, Arena R, et al. Guidelines for adult stroke rehabilitation and recovery: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2016 Jun;47(6):e98-169.Full text  Abstract

302. Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med. 2001 Sep;16(9):606-13.Full text  Abstract

303. Silverman JJ, Galanter M, Jackson-Triche M, et al. The American Psychiatric Association practice guidelines for the psychiatric evaluation of adults. Am J Psychiatry. 2015 Aug 1;172(8):798-802.Full text  Abstract

304. Boden JM, Fergusson DM. Alcohol and depression. Addiction. 2011 May;106(5):906-14. Abstract

305. van den Berghe G, Wouters P, Weekers F, et al. Intensive insulin therapy in critically ill patients. N Engl J Med. 2001 Nov 8;345(19):1359-67.Full text  Abstract

306. NICE-SUGAR Study Investigators; Finfer S, Chittock DR, Su SY, et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med. 2009 Mar 26;360(13):1283-97.Full text  Abstract

307. Yamada T, Shojima N, Noma H, et al. Glycemic control, mortality, and hypoglycemia in critically ill patients: a systematic review and network meta-analysis of randomized controlled trials. Intensive Care Med. 2017 Jan;43(1):1-15. Abstract

308. Yatabe T, Inoue S, Sakaguchi M, et al. The optimal target for acute glycemic control in critically ill patients: a network meta-analysis. Intensive Care Med. 2017 Jan;43(1):16-28. Abstract

309. McCall AL, Lieb DC, Gianchandani R, et al. Management of individuals with diabetes at high risk for hypoglycemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab. 2023 Feb 15;108(3):529-62.Full text  Abstract

310. Pasquel FJ, Lansang MC, Dhatariya K, et al. Management of diabetes and hyperglycaemia in the hospital. Lancet Diabetes Endocrinol. 2021 Mar;9(3):174-88.Full text  Abstract

311. Rehman A, Setter SM, Vue MH. Drug-induced glucose alterations part 2: drug-Induced hyperglycemia. Diabetes Spect. 2011 Nov;24(4):234-8.Full text

312. National Institute for Health and Care Excellence. Diabetic foot problems: prevention and management. October 2019 [internet publication].Full text

313. American Diabetes Association Professional Practice Committee. 12. Retinopathy, neuropathy, and foot care: standards of care in diabetes - 2024. Diabetes Care. 2024 Jan 1;47(suppl 1):S231-43.Full text  Abstract

314. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a meta-analysis. Chest. 2004 Jun;125(6):2309-21. Abstract

315. Au DH, Curtis JR, Every NR, et al. Association between inhaled beta-agonists and the risk of unstable angina and myocardial infarction. Chest. 2002 Mar;121(3):846-51. Abstract

316. Bauer M, Severus E, Köhler S, et al. World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders. part 2: maintenance treatment of major depressive disorder-update 2015. World J Biol Psychiatry. 2015 Feb;16(2):76-95. Abstract

317. Hoffelt C, Gross T. A review of significant pharmacokinetic drug interactions with antidepressants and their management. Ment Health Clin. 2016 2016 Mar 8;6(1):35-41.Full text  Abstract

318. Van Leeuwen E, van Driel ML, Horowitz MA, et al. Approaches for discontinuation versus continuation of long-term antidepressant use for depressive and anxiety disorders in adults. Cochrane Database Syst Rev. 2021 Apr 15;(4):CD013495.Full text  Abstract

319. Qaseem A, Owens DK, Etxeandia-Ikobaltzeta I, et al. Nonpharmacologic and pharmacologic treatments of adults in the acute phase of major depressive disorder: a living clinical guideline from the American College of Physicians. Ann Intern Med. 2023 Feb;176(2):239-52.Full text  Abstract

320. Liamis G, Milionis H, Elisaf M. A review of drug-induced hyponatremia. Am J Kidney Dis. 2008 Jul;52(1):144-53. Abstract

321. Liamis G, Filippatos TD, Elisaf MS. Thiazide-associated hyponatremia in the elderly: what the clinician needs to know. J Geriatr Cardiol. 2016 Feb;13(2):175-82.Full text  Abstract

322. Boyer EW, Shannon M. The serotonin syndrome. N Engl J Med. 2005 Mar 17;352(11):1112-20. Abstract

323. Buckley NA, Dawson AH, Isbister GK. Serotonin syndrome. BMJ. 2014 Feb 19;348:g1626. Abstract

324. Volpi-Abadie J, Kaye AM, Kaye AD. Serotonin syndrome. Ochsner J. 2013 Winter;13(4):533-40.Full text  Abstract

325. Chander WP, Singh N, Mukhiya GK. Serotonin syndrome in maintenance haemodialysis patients following sertraline treatment for depression. J Indian Med Assoc. 2011 Jan;109(1):36-7. Abstract

326. Voican CS, Corruble E, Naveau S, et al. Antidepressant-induced liver injury: a review for clinicians. Am J Psychiatry. 2014 Apr;171(4):404-15.Full text  Abstract

327. Saraghi M, Golden LR, Hersh EV. Anesthetic considerations for patients on antidepressant therapy-part I. Anesth Prog. 2017 Winter;64(4):253-61.Full text  Abstract

328. Harbell MW, Dumitrascu C, Bettini L, et al. Anesthetic considerations for patients on psychotropic drug therapies. Neurol Int. 2021 Nov 29;13(4):640-58.Full text  Abstract

329. Tisdale JE, Chung MK, Campbell KB, et al. Drug-induced arrhythmias: a scientific statement from the American Heart Association. Circulation. 2020 Oct 13;142(15):e214-233.Full text  Abstract

330. Siu AL, US Preventive Services Task Force (USPSTF), Bibbins-Domingo K, et al. Screening for depression in adults: US Preventive Services Task Force recommendation statement. JAMA. 2016 Jan 26;315(4):380-7.Full text  Abstract

331. Halperin D, Reber G. Influence of antidepressants on hemostasis. Dialogues Clin Neurosci. 2007;9(1):47-59.Full text  Abstract

332. Nochaiwong S, Ruengorn C, Awiphan R, et al. Use of serotonin reuptake inhibitor antidepressants and the risk of bleeding complications in patients on anticoagulant or antiplatelet agents: a systematic review and meta-analysis. Ann Med. 2022 Dec;54(1):80-97.Full text  Abstract

333. Loke YK, Trivedi AN, Singh S. Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and non-steroidal anti-inflammatory drugs. Aliment Pharmacol Ther. 2008 Jan 1;27(1):31-40.Full text  Abstract

334. Flowers L. Nicotine replacement therapy. Am J Psychiatry Resid J. 2016 Jun;11(6):4-7.Full text

335. Desai HD, Seabolt J, Jann MW. Smoking in patients receiving psychotropic medications: a pharmacokinetic perspective. CNS Drugs. 2001;15(6):469-94. Abstract

336. Oliveira P, Ribeiro J, Donato H, et al. Smoking and antidepressants pharmacokinetics: a systematic review. Ann Gen Psychiatry. 2017 Mar 6:16:17.Full text  Abstract

337. DiMatteo MR, Lepper HS, Croghan TW. Depression is a risk factor for noncompliance with medical treatment: meta-analysis of the effects of anxiety and depression on patient adherence. Arch Intern Med. 2000 Jul 24;160(14):2101-7.Full text  Abstract

338. Lapa ME, Swabe GM, Rollman BL, et al. Assessment of depression and adherence to guideline-drected medical therapies following percutaneous coronary intervention. JAMA Netw Open. 2022 Dec 1;5(12):e2246317.Full text  Abstract

339. Poletti V, Pagnini F, Banfi P, et al. The role of depression on treatment adherence in patients with heart failure-a systematic review of the literature. Curr Cardiol Rep. 2022 Dec;24(12):1995-2008.Full text  Abstract

340. Prina AM, Cosco TD, Dening T, et al. The association between depressive symptoms in the community, non-psychiatric hospital admission and hospital outcomes: a systematic review. J Psychosom Res. 2015 Jan;78(1):25-33.Full text  Abstract

341. Clarke DM, Currie KC. Depression, anxiety and their relationship with chronic diseases: a review of the epidemiology, risk and treatment evidence. Med J Aust. 2009 Apr 6;190(s7):S54-60.Full text  Abstract

342. Archer G, Kuh D, Hotopf M, et al. Association between lifetime affective symptoms and premature mortality. JAMA Psychiatry. 2020 Aug 1;77(8):806-13.Full text  Abstract

343. Machado MO, Veronese N, Sanches M, et al. The association of depression and all-cause and cause-specific mortality: an umbrella review of systematic reviews and meta-analyses. BMC Med. 2018 Jul 20;16(1):112.Full text  Abstract

344. Streck JM, Rigotti NA, Livingstone-Banks J, et al. Interventions for smoking cessation in hospitalised patients. Cochrane Database Syst Rev. 2024 May 21;(5):CD001837.Full text  Abstract

345. Theodoulou A, Chepkin SC, Ye W, et al. Different doses, durations and modes of delivery of nicotine replacement therapy for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 19;(6):CD013308.Full text  Abstract

346. Rigotti NA, Kruse GR, Livingstone-Banks J, et al. Treatment of tobacco smoking: a review. JAMA. 2022 Feb 8;327(6):566-77. Abstract

347. Agrawal S, Evison M, Ananth S, et al. Medical management of inpatients with tobacco dependency. Thorax. 2024 Mar 26;79(suppl 1):3-11. Abstract

348. Thomas KH, Dalili MN, López-López JA, et al. Comparative clinical effectiveness and safety of tobacco cessation pharmacotherapies and electronic cigarettes: a systematic review and network meta-analysis of randomized controlled trials. Addiction. 2022 Apr;117(4):861-76.Full text  Abstract

349. Livingstone-Banks J, Fanshawe TR, Thomas KH, et al. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2023 Jun 28;(6):CD006103.Full text

350. Joint British Diabetes Societies for Inpatient Care. Management of hyperglycaemia and steroid (glucocorticosteroid) therapy. January 2023 [internet publication].Full text

351. Koning ACAM, van der Meulen M, Schaap D, et al. Neuropsychiatric adverse effects of synthetic glucocorticoids: a systematic review and meta-analysis. J Clin Endocrinol Metab. 2024 May 17;109(6):e1442-51.Full text  Abstract

352. Judd LL, Schettler PJ, Brown ES, et al. Adverse consequences of glucocorticoid medication: psychological, cognitive, and behavioral effects. Am J Psychiatry. 2014 Oct;171(10):1045-51.Full text  Abstract

353. Kenna HA, Poon AW, de los Angeles CP, et al. Psychiatric complications of treatment with corticosteroids: review with case report. Psychiatry Clin Neurosci. 2011 Oct;65(6):549-60.Full text  Abstract

354. Fardet L, Nazareth I, Whitaker HJ, et al. Severe neuropsychiatric outcomes following discontinuation of long-term glucocorticoid therapy: a cohort study. J Clin Psychiatry. 2013 Apr;74(4):e281-6. Abstract

355. Warrington TP, Bostwick JM. Psychiatric adverse effects of corticosteroids. Mayo Clin Proc. 2006 Oct;81(10):1361-7.Full text  Abstract

Use of this content is subject to our disclaimer